What is the 13F Pro Quality Score for WHWK?

13F Pro ranks Whitehawk Therapeutics, Inc. (WHWK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View WHWK's current score at https://13fpro.ai/research/WHWK (free sign-up required for the full ranking).

Which hedge funds own the most WHWK stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of WHWK include QVT Financial, ORBIMED ADVISORS, SUVRETTA CAPITAL MANAGEMENT,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/WHWK as soon as new 13F filings post.

Where does 13F Pro source WHWK data?

All Whitehawk Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Whitehawk Therapeutics, Inc. files with the SEC under CIK 1422142. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is WHWK in?

Whitehawk Therapeutics, Inc. (WHWK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is WHWK research updated on 13F Pro?

WHWK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Whitehawk Therapeutics, Inc.(WHWK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1422142 WHWK stock profile & AI dashboard →

13F Pro Quality Score

9.6/100

Rank #2,816 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

2.0/100

Profitability

4.6/100

Balance Sheet

15.1/100

Earnings Quality

30.0/100

Free Cash Flow

1.8/100

Institutional Flow

73.7/100

Revenue Scale

2.9/100

Dilution Risk

2.4/100

WHWK Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Whitehawk Therapeutics, Inc. (WHWK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores WHWK at 9.6/100 on a 32-signal composite quality model, placing it at rank #2,816 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (1.8) and revenue growth (2.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Whitehawk Therapeutics, Inc. reports net income of $-22.2M, free cash flow of $-22.2M. Top institutional holders of WHWK by reported 13-F value include QVT Financial, ORBIMED ADVISORS, SUVRETTA CAPITAL MANAGEMENT,, based on the most recent SEC filings. WHWK trades on the Nasdaq exchange and files with the SEC under CIK 1422142. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate WHWK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Whitehawk Therapeutics, Inc. directly from SEC EDGAR. Whitehawk Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 9 and 60 since 2024, currently 9.6 — a declining long-term trajectory across 15 quarterly and live scoring snapshots.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-22.2M

Free Cash Flow

Q1 2026

$-22.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-72.5% YoY

$7.1MFY 2025

FY22 $15.2MFY23 $24.4MFY24 $26.0MFY25 $7.1M

Net Income

+67.7% YoY

$-20.6MFY 2025

FY22 $-60.5MFY23 $-65.8MFY24 $-63.7MFY25 $-20.6M

Operating Income

-69.6% YoY

$-114.4MFY 2025

FY22 $-62.7MFY23 $-71.9MFY24 $-67.5MFY25 $-114.4M

EPS (Diluted)

+72.0% YoY

$-0.33FY 2025

FY22 $-1.34FY23 $-1.22FY24 $-1.18FY25 $-0.33

Total Assets

+114.5% YoY

$150.8MFY 2025

FY22 $184.2MFY23 $132.4MFY24 $70.3MFY25 $150.8M

Op. Cash Flow

-63.6% YoY

$-97.4MFY 2025

FY22 $-49.6MFY23 $-59.7MFY24 $-59.5MFY25 $-97.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2018
Revenue	$7.1M -72.5%	$26.0M +6.7%	$24.4M +60.1%	$15.2M +1.4%	$15.0M -25.6%	$20.2M
Net Income	$-20.6M +67.7%	$-63.7M +3.2%	$-65.8M -8.7%	$-60.5M -1639.9%	$-3.5M +66.5%	$-10.4M
Operating Income	$-114.4M -69.6%	$-67.5M +6.2%	$-71.9M -14.8%	$-62.7M -2359.0%	$-2.5M +77.2%	$-11.2M
EPS (Diluted)	$-0.33 +72.0%	$-1.18 +3.3%	$-1.22 +9.3%	$-1.34	—	—
Total Assets	$150.8M +114.5%	$70.3M -46.9%	$132.4M -28.1%	$184.2M +878.7%	$18.8M -70.6%	$64.1M
Operating Cash Flow	$-97.4M -63.6%	$-59.5M +0.2%	$-59.7M -20.2%	$-49.6M -290.8%	$-12.7M -118.7%	$-5.8M

AI Insight: WHWK Financial Trends

Whitehawk's revenue collapsed to zero in Q2 2025 while cash burn accelerated, depleting equity from $222M to $116M in one year.

• Revenue dropped from $7M in Q1 2025 to $0M from Q2 2025 onwards, indicating complete loss of commercial activity.

• Net income swung from $73M gain in Q1 2025 to consistent losses averaging $24M per quarter since Q2 2025.

• Equity declined from peak of $222M in Q1 2025 to $116M in Q1 2026, a 48% reduction in four quarters.

⚠ Operating cash flow burn worsened to $22M in Q1 2026 from $12M in Q1 2025, suggesting deteriorating cost control.

⚠ At current burn rate of ~$20M per quarter, remaining equity provides roughly 5-6 quarters of runway before financing needs.

AI Insight: WHWK Ratio Trends

Whitehawk's profitability metrics remain deeply negative with ROE deteriorating from -45.2% in Q3 2025 to -76.4% in Q1 2026.

• ROE worsened from -45.2% in Q3 2025 to -76.4% in Q1 2026, indicating declining profitability.

• ROA dropped from -42.5% in Q3 2025 to -69.8% in Q1 2026, showing deteriorating asset efficiency.

• ROIC declined from -49.8% in Q3 2025 to -81.0% in Q1 2026, reflecting poor capital allocation.

⚠ Sparse data availability across most quarters limits comprehensive trend analysis of core operating metrics.

⚠ All profitability measures remain substantially negative, indicating ongoing operational challenges for this healthcare company.

Get alerted when WHWK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Whitehawk Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of WHWK

QVT Financial LP
$15.9M4,615,709 sh
ORBIMED ADVISORS LLC
$14.4M4,166,000 sh
SUVRETTA CAPITAL MANAGEMENT, LLC
$12.8M3,700,000 sh
ACUTA CAPITAL PARTNERS, LLC
$11.8M3,410,402 sh
Avoro Capital Advisors LLC
$9.8M2,849,402 sh
KVP Capital Advisors, LP
$7.5M2,165,997 sh
Siren, L.L.C.
$7.2M2,082,000 sh
Yu Fan
$7.1M2,070,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.5M1,315,770 sh
ACORN CAPITAL ADVISORS, LLC
$3.9M1,139,363 sh

Fund	Value	Shares
QVT Financial LP	$15.9M	4,615,709
ORBIMED ADVISORS LLC	$14.4M	4,166,000
SUVRETTA CAPITAL MANAGEMENT, LLC	$12.8M	3,700,000
ACUTA CAPITAL PARTNERS, LLC	$11.8M	3,410,402
Avoro Capital Advisors LLC	$9.8M	2,849,402
KVP Capital Advisors, LP	$7.5M	2,165,997
Siren, L.L.C.	$7.2M	2,082,000
Yu Fan	$7.1M	2,070,000
VANGUARD CAPITAL MANAGEMENT LLC	$4.5M	1,315,770
ACORN CAPITAL ADVISORS, LLC	$3.9M	1,139,363

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put WHWK on your watchlist

Track score changes the day Whitehawk Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is WHWK a good stock to buy?

13F Pro's AI-powered analysis of Whitehawk Therapeutics, Inc. (WHWK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for WHWK are available on the WHWK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own WHWK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling WHWK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Whitehawk Therapeutics, Inc.'s investment landscape.